London, Feb 2, 2026, 08:26 GMT — Regular session
- GSK shares edged up 0.3% in early London trading, hovering close to their recent peaks.
- Investors are gearing up for GSK’s full-year and Q4 earnings due Feb. 4.
- A weekend report indicated the drugmaker is considering future cost cuts and adjustments to its European manufacturing operations.
Shares of GSK (GSK.L) edged higher by 0.3% to 1,882.5 pence as of 0826 GMT, moving within a range of 1,875 to 1,890 pence earlier. Over the last 52 weeks, the stock has fluctuated between 1,242.5 and 1,909.5 pence. (Investing)
Investors are gearing up for GSK’s fourth-quarter and full-year results, scheduled for Wednesday, Feb. 4. The company plans to release the figures at 0700 GMT, followed by a management webcast at 1100 GMT. (GSK)
What matters now isn’t just the numbers but the message. The initial results under new CEO Luke Miels will signal the group’s stance on spending discipline, product launches, and the intensity of its long-term growth ambitions.
The Times reported Sunday that GSK is exploring possible cost savings and manufacturing tweaks in Europe to unlock cash for new product launches. Analysts in the City have mentioned a potential efficiency programme around £1 billion, though no formal cost-cutting measures are expected soon. (The Times)
A company-compiled analyst consensus dated Jan. 20 forecasts 2025 turnover at 32.5 billion pounds and operating profit around 9.7 billion pounds. For Q4, the consensus projects turnover of 8.5 billion pounds and “core” earnings per share at 23 pence — with “core” reflecting the company’s adjusted metric excluding certain one-off items. (GSK)
The bigger picture is confidence — and mounting pressure. The Financial Times noted GSK’s shares have climbed roughly 40% since April 2025. Investors are eager for Miels to prove the pipeline can counter upcoming patent losses, all while aiming to close the gap with UK rival AstraZeneca in size. (Financial Times)
Broader markets appear jittery as a busy week of earnings reports and central-bank meetings looms. Investors are still reeling from a steep drop in precious metals, while equity futures slid in Asia overnight. (Reuters)
In the UK, all eyes are on the Bank of England this week as policymakers are set to hold rates steady on Thursday. Deutsche Bank Chief UK Economist Sanjay Raja noted, “The timing of those rate cuts … is coming increasingly into question.” (Reuters)
Still, plenty could trip things up. If guidance disappoints or investors sense cost pressures the company downplays, that initial surge in the stock could vanish quickly — especially with multiple late-stage trial results looming and little margin for errors in execution.
Wednesday brings the earnings report and management webcast. Traders will be tuning in for concrete figures on savings, updates on the European manufacturing footprint, and the company’s outlook for 2026 after a solid rally in its shares.
